Levofloxacin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Skin Diseases, Infectious
Conditions
Skin Diseases, Infectious
Trial Timeline
Jan 1, 1993 → Apr 1, 1994
NCT ID
NCT00257062About Levofloxacin
Levofloxacin is a phase 3 stage product being developed by Johnson & Johnson for Skin Diseases, Infectious. The current trial status is completed. This product is registered under clinical trial identifier NCT00257062. Target conditions include Skin Diseases, Infectious.
What happened to similar drugs?
16 of 20 similar drugs in Skin Diseases, Infectious were approved
Approved (16) Terminated (4) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002249 | Phase 1 | Completed |
| NCT00210886 | Phase 3 | Completed |
| NCT00645437 | Phase 1 | Completed |
| NCT00236652 | Phase 3 | Completed |
| NCT00044473 | Phase 3 | Completed |
| NCT00236522 | Phase 3 | Completed |
| NCT00034736 | Phase 3 | Completed |
| NCT00236821 | Phase 3 | Completed |
| NCT00236808 | Phase 3 | Completed |
| NCT00249197 | Phase 3 | Completed |
| NCT00269932 | Phase 3 | Completed |
| NCT00249210 | Phase 3 | Completed |
| NCT00258089 | Phase 3 | Completed |
| NCT00258102 | Phase 3 | Completed |
| NCT00257062 | Phase 3 | Completed |
| NCT00257036 | Phase 2/3 | Completed |
| NCT00257049 | Phase 2/3 | Completed |
| NCT00257140 | Phase 2/3 | Completed |
Competing Products
20 competing products in Skin Diseases, Infectious